On February 23, 2016 TG Therapeutics, Inc. (Nasdaq:TGTX) reported that the United States Patent and Trademark Office (USPTO) has issued a patent for the composition of matter of TGR-1202, the Company’s orally available PI3K delta inhibitor (Press release, TG Therapeutics, FEB 23, 2016, View Source [SID:1234509146]). Schedule your 30 min Free 1stOncology Demo! The patent, U.S. Patent No. 9,150,579 specifically covers TGR-1202, pharmaceutical compositions containing TGR-1202, and its use for treating various forms of leukemia, including chronic lymphocytic leukemia (CLL). The patent was issued to Rhizen Pharmaceuticals SA and is exclusively licensed to TG Therapeutics pursuant to the Company’s existing license agreement with Rhizen Pharmaceuticals. The issuance affords patent protection for TGR-1202 in the US through July of 2033, exclusive of patent term extensions, which have the potential to extend beyond this date. TGR-1202 is currently in Phase 3 clinical development.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are happy to report the issuance of the first U.S. patent for TGR-1202 which provides composition of matter patent protection until at least 2033 and possibly longer with patent term extensions. We believe this issuance strengthens our intellectual property position and should provide substantial market exclusivity for TGR-1202," stated Michael S. Weiss, the Company’s Executive Chairman and Interim CEO. Mr. Weiss continued, "We look forward to continuing to strengthen our intellectual property position through the issuance of additional patents for our portfolio products both individually and in combination in the US and abroad."